Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases

Fig. 1

IgG levels before initiation of Ig therapy, peak and trough serum IgG levels (during high-dose IVIg therapy) and peak levels during SCIg therapy. Values represent mean values and error bars standard deviation (if multiple measurements are available). The dashed lines represent the upper and lower limit of the normal range

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096